艾克美制药 ALKS
$45.90 +$1.36 (+3.05%)
休市 · Nov 6, 9:50 pm ET · 最新盘后价 $46.01 +0.24%
开盘$44.19
昨收$44.54
当日区间$44.07 – $45.94
成交量1.67M
市值$7.71B
市盈率（TTM）–
股息率–
股权结构与仓位
谁在持有、谁在做空，以及大资金的流向
机构持股比例109.1%-0.08 个百分点，较上季度
持仓机构数516-1 ，较上季度
内部人近期交易24次买入 / 26次卖出净卖出
空头持仓比例11.35% 占流通股回补天数 9.1 · 截至 15 Oct 2026
卖空成交量占比27.0%近5日成交量平均占比
卖空成交量占当日成交量比例
大单净流入，近20个交易日
大单买入减卖出的净额（美元）。该窗口期内：−$32.73M（10个净流入日，10个净流出日）。
按单量净流入，近20个交易日
超大单/大单近似机构级别交易；中单/小单近似散户级别交易。各档买入减卖出净额，按窗口期累计。
已披露的前五大股东合计持有39.7%的流通股。
最大股东
按投资者类型
过去6次双周报告中（31 Jul 2026至15 Oct 2026），空头持仓占流通股比例已从8.59%升至11.35%。
近期机构持仓变动
| 股东 | 类型 | 期间 | 持股变动 | 新持股比例 |
|---|---|---|---|---|
| T. Rowe Price Group, Inc. | Mutual Fund | 2026/Q3 | +2,269,423 | 4.7% |
| Adage Capital Management, L.P. | Hedge Fund | 2026/Q3 | +1,368,000 | 0.8% |
| Bain Capital Life Sciences Investors, LLC | VC/PE Fund | 2026/Q3 | +1,327,938 | 1.2% |
| Holocene Advisors, LP | Hedge Fund | 2026/Q3 | +1,284,146 | 2.1% |
| Franklin Resources | Mutual Fund | 2026/Q3 | +987,702 | 0.7% |
| Summit Partners Public Asset Management, LLC | Hedge Fund | 2026/Q3 | +950,234 | 0.6% |
| BNPP Asset Management Holding | Mutual Fund | 2026/Q3 | +929,290 | 0.6% |
| BlackRock | Mutual Fund | 2026/Q3 | +921,329 | 17.4% |
| Frontier Capital Management | Mutual Fund | 2026/Q3 | +659,562 | 0.4% |
| Victory Capital Management Inc. | Mutual Fund | 2026/Q3 | +607,780 | 0.5% |
| D. E. Shaw & Co., L.P. | Hedge Fund | 2026/Q3 | +601,734 | 0.8% |
| Artia Global Partners LP | VC/PE Fund | 2026/Q3 | +448,964 | 0.3% |
| Driehaus Capital Management LLC | Mutual Fund | 2026/Q3 | +446,846 | 0.7% |
| MetLife Investment Management, LLC | Mutual Fund | 2026/Q3 | +424,072 | 0.3% |
| Deep Track Capital, LP | VC/PE Fund | 2026/Q3 | +409,677 | 2.4% |
按报告期列出的机构买卖动态，变动幅度从大到小排列。
内部人交易
| 日期 | 内部人 | 职位 | 交易类型 | 股数 | 价格 | 交易后持股 |
|---|---|---|---|---|---|---|
| 7 Oct 2026 | Joshua Reed | Senior Vice President | Derivative Exercise and Sale | -4,069 | $40.11 | 5,095 |
| 7 Oct 2026 | Joshua Reed | Senior Vice President | Derivative Exercise and Retained | +5,095 | – | 5,095 |
| 6 Oct 2026 | Anne Michelle Whitaker | Independent Director | Other Derivative Acquisition | +7,239 | – | 7,239 |
| 6 Oct 2026 | Anne Michelle Whitaker | Independent Director | Other Derivative Acquisition | +17,998 | $41.45 | 17,998 |
| 1 Oct 2026 | David Gaffin | Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary | Automatic Disposition | -2,034 | $41.03 | 221,388 |
| 2 Sep 2026 | David Gaffin | Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary | Automatic Disposition | -2,034 | $48.01 | 223,422 |
| 31 Aug 2026 | Craig Hopkinson | Executive VP of Research & Development and Chief Medical Officer | Automatic Disposition | -4,000 | $46.99 | 65,389 |
| 31 Aug 2026 | Craig Hopkinson | Executive VP of Research & Development and Chief Medical Officer | Derivative Exercise and Sale | -5,000 | $46.99 | 65,389 |
| 16 Aug 2026 | Christian Nichols | Chief Commercial Officer | Automatic Disposition | -7,576 | $49.65 | 102,193 |
| 4 Aug 2026 | Blair Jackson | Chief Executive Officer | Other Derivative Acquisition | +217,534 | $49.61 | 124,305 |
| 2 Aug 2026 | Nancy Snyderman | Independent Director | Derivative Exercise and Sale | -44,472 | $50.35 | 36,178 |
| 2 Aug 2026 | Craig Hopkinson | Executive VP of Research & Development and Chief Medical Officer | Automatic Disposition | -4,000 | $48.58 | 69,389 |
| 2 Aug 2026 | Craig Hopkinson | Executive VP of Research & Development and Chief Medical Officer | Derivative Exercise and Sale | -5,000 | $48.58 | 69,389 |
| 2 Aug 2026 | David Gaffin | Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary | Automatic Disposition | -2,034 | $48.58 | 225,456 |
| 5 Jul 2026 | David Gaffin | Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary | Automatic Disposition | -2,034 | $54.03 | 227,490 |
| 30 Jun 2026 | Craig Hopkinson | Executive VP of Research & Development and Chief Medical Officer | Automatic Disposition | -4,000 | $52.13 | 73,389 |
| 30 Jun 2026 | Craig Hopkinson | Executive VP of Research & Development and Chief Medical Officer | Derivative Exercise and Sale | -5,000 | $51.46 | 73,389 |
| 11 Jun 2026 | Christopher I. Wright | Independent Director | Automatic Disposition | -2,000 | $45.10 | 25,680 |
| 3 Jun 2026 | David Gaffin | Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary | Automatic Disposition | -2,034 | $43.05 | 229,524 |
| 31 May 2026 | Craig Hopkinson | Executive VP of Research & Development and Chief Medical Officer | Automatic Disposition | -4,000 | $41.67 | 77,389 |
数据来自Form 4/Form 144申报文件。负数为减持（出售、赠予或代扣税款股份），正数为增持。
空头持仓（按报告期）
| 报告日期 | 空头股数 | 占流通股比例 | 回补天数 |
|---|---|---|---|
| 15 Oct 2026 | 19,048,577 | 11.4% | 9.1 |
| 30 Sep 2026 | 17,821,179 | 10.6% | 6.3 |
| 15 Sep 2026 | 15,156,775 | 9.0% | 10.7 |
| 31 Aug 2026 | 14,717,404 | 8.8% | 11.8 |
| 14 Aug 2026 | 14,761,342 | 8.8% | 10.2 |
| 31 Jul 2026 | 14,406,911 | 8.6% | 7.7 |
暂无评论——快来第一个聊聊 ALKS。
登录后参与讨论。